Current Report Filing (8-k)
March 11 2022 - 4:04PM
Edgar (US Regulatory)
0001514183
false
0001514183
2022-03-11
2022-03-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported): March
11, 2022
SILO PHARMA, INC.
(Name of registrant in its charter)
Delaware |
|
000-54872 |
|
27-3046338 |
(State or jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
incorporation or organization) |
|
|
|
Identification No.) |
560 Sylvan Ave, Suite 3160
Englewood Cliffs, NJ 07632
(Address of principal executive offices)
(718) 400-9031
(Registrant’s telephone number)
N/A
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instructions
A.2 below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act: None.
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On March 11, 2022, the Company held its special meeting
of stockholders (the “Special Meeting”). A total of 53,859,947 shares of common stock constituting a quorum were represented
in person or by valid proxies at the Special Meeting. The final results for of the matter submitted
to a vote of stockholders at the Special Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange
Commission on February 14, 2022, is as follows:
Proposal
1. At the Special Meeting, the stockholders approved granting discretionary authority to the Company’s Board of Directors
to amend the Company’s Certificate of Incorporation to effect one or more consolidations of the Company’s issued and outstanding
shares of common stock, pursuant to which the shares of common stock would be combined and reclassified into one share of common stock
at a ratio within the range from 1-for-5 up to 1-for-50 (the “Reverse Stock Split”), provided that, (X) that the Company shall
not effect Reverse Stock Splits that, in the aggregate, exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than the
first anniversary of the record date of the Special Meeting, or February 8, 2023. The voting results were as follows:
For |
|
Against |
|
Abstain |
|
53,847,792 |
|
11,915 |
|
240 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SILO PHARMA, INC. |
|
|
|
Date: March 11, 2022 |
By: |
/s/ Eric Weisblum |
|
|
Eric Weisblum,
Chief Executive Officer |
Silo Pharma (QB) (USOTC:SILO)
Historical Stock Chart
From May 2024 to Jun 2024
Silo Pharma (QB) (USOTC:SILO)
Historical Stock Chart
From Jun 2023 to Jun 2024